中药辅助治疗乳腺癌疗效与安全性的随机对照试验荟萃分析
该荟萃分析纳入81项随机对照试验共7215例乳腺癌患者,比较单纯西医治疗与联合中药治疗的差异。结果显示联合中药组肿瘤缓解率、中位进展时间、总生存期及3年无进展生存率等均优于单纯西医组,但研究需进一步按肿瘤分期和干预类型分层。
要点
- 联合中药组肿瘤缓解率52%(RECIST1.1)或67%(WHO标准),高于单纯西医组的38%或53%。
- 联合中药组中位进展时间延长2.79个月,总生存期延长1.90个月。
- 联合中药组3年无进展生存率及2年、5年总生存率均有提高。
核心结论
- 辅助中药治疗可能在肿瘤缓解和生存方面为乳腺癌患者带来临床获益。
研究设计与样本
- 荟萃分析纳入81项随机对照试验,共7215例受试者,检索8个数据库,比较单纯西医治疗与联合中药治疗。
主要发现
- RECIST1.1标准下联合中药组完全或部分缓解率52%,单纯西医组38%,风险比1.31(95% CI 1.15-1.50,P<0.00001)。
- WHO标准下联合中药组缓解率67%,单纯西医组53%,风险比1.25(95% CI 1.18-1.98,P<0.00001)。
- 联合中药组中位进展时间延长2.79个月(P<0.00001),总生存期延长1.90个月(P<0.00001)。
- 联合中药组3年无进展生存率(P=0.002)、2年总生存率(P=0.0002)和5年总生存率(P=0.006)均有提高。
关键数值与推荐
- 肿瘤缓解评估采用RECIST1.1和WHO标准,联合中药组缓解率分别为52%和67%。
- 风险比1.31(95% CI 1.15-1.50)对应RECIST1.1标准下联合中药对比单纯西医的缓解率。
- 风险比1.25(95% CI 1.18-1.98)对应WHO标准下联合中药对比单纯西医的缓解率。
临床怎么用
- 在常规西医治疗基础上,可考虑联合中药以改善肿瘤缓解和生存结局。
- 需结合患者肿瘤分期和具体中药干预类型个体化评估获益。
局限性
- 研究建议未来需按肿瘤分期和干预类型进一步分层开展临床研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Breast cancer is currently the most common cancer in women, and it accounts for 11.6% of all cancer diagnoses in 2018. Breast cancer patients frequently resort to alternative medicine in addition to conventional Western therapy. This study is to evaluate clinical effectiveness of Chinese herbal medicine (CHM) on breast cancer by conducting meta-analyses on 81 randomized controlled trials (RCTs) with a total of 7215 subjects from eight databases. All RCTs compared patients using Western therapy alone and those using additional CHM therapy to evaluate the difference of primary (tumor response, mean time to progression (mTTP), overall survival (OS) and progression free survival (PFS)) and secondary outcome measures (tumor markers). Results showed that under the RECIST1.1 criteria, 52% patients with additional CHM therapy (67%, under WHO criteria) achieved either a complete response (CR) or a partial response (PR), compared to 38% patients with Western therapy alone (53%, under the WHO criteria). The risk ratio was 1.31 ([Formula: see text] < 0.00001, 95% CI = 1.15-1.50) for patients with CHM plus Western therapy and 1.25 ([Formula: see text] < 0.00001, 95% CI = 1.18-1.98) for those with Western therapy. Moreover, patients with complementary CHM therapy were associated with an mTTP of 2.79 months longer ([Formula: see text] < 0.00001) and an OS of 1.90 months longer ([Formula: see text] < 0.00001); they also had an increase in 3-year PFS ([Formula: see text]= 0.002), 2- ([Formula: see text]= 0.0002) and 5-year ([Formula: see text]= 0.006) OS rates. Therefore, complementary CHM therapy might demonstrate clinical benefits for breast cancer patients in terms of tumor response and survival. Clinical studies with further stratification of tumor stages and intervention types are highly warranted.
引用
- Ho VW, Tan HY, Guo W, et al. Efficacy and Safety of Chinese Herbal Medicine on Treatment of Breast Cancer: A Meta-analysis of Randomized Controlled Trials. Am J Chin Med. 2021. PMID: 34530698. doi:10.1142/S0192415X21500737
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。